Limit Confusion and Other Issues With Paxlovid

July 2022

You can help prevent problems when patients taking nirmatrelvir/ritonavir (Paxlovid) for COVID-19 are admitted.

High-risk OUTpatients with a positive COVID-19 test should start this antiviral combo within 5 days of symptom onset.

And if a patient is hospitalized before the course is complete, clinicians may want to finish it.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote